Literature DB >> 32302456

Potential of heparin and nafamostat combination therapy for COVID-19.

Hidesaku Asakura1, Haruhiko Ogawa2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32302456     DOI： 10.1111/jth.14858

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  38 in total

Review 1.  Comparison of Cell Fusions Induced by Influenza Virus and SARS-CoV-2.

Authors:  Chuyuan Zhang; Xinjie Meng; Hanjun Zhao
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

2.  Investigation of the disease process and drug combinations in patients with suspected/confirmed COVID-19 using favipiravir.

Authors:  Muhammet Ali Oruç; Hatice Öz; Onur Öztürk
Journal:  Int J Clin Pract       Date:  2021-03-29       Impact factor: 3.149

Review 3.  Anticoagulation Options for Coronavirus Disease 2019 (COVID-19)-Induced Coagulopathy.

Authors:  Alla Turshudzhyan
Journal:  Cureus       Date:  2020-05-16

Review 4.  While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?

Authors:  Francisco J Barrantes
Journal:  Front Physiol       Date:  2020-07-03       Impact factor: 4.566

Review 5.  COVID-19 Pandemic: Cardiovascular Complications and Future Implications.

Authors:  Dhrubajyoti Bandyopadhyay; Tauseef Akhtar; Adrija Hajra; Manasvi Gupta; Avash Das; Sandipan Chakraborty; Ipsita Pal; Neelkumar Patel; Birendra Amgai; Raktim K Ghosh; Gregg C Fonarow; Carl J Lavie; Srihari S Naidu
Journal:  Am J Cardiovasc Drugs       Date:  2020-08       Impact factor: 3.571

6.  Consideration of Tranexamic Acid Administration to COVID-19 Patients.

Authors:  Haruhiko Ogawa; Hidesaku Asakura
Journal:  Physiol Rev       Date:  2020-10-01       Impact factor: 37.312

Review 7.  Recent advances in developing small-molecule inhibitors against SARS-CoV-2.

Authors:  Rong Xiang; Zhengsen Yu; Yang Wang; Lili Wang; Shanshan Huo; Yanbai Li; Ruiying Liang; Qinghong Hao; Tianlei Ying; Yaning Gao; Fei Yu; Shibo Jiang
Journal:  Acta Pharm Sin B       Date:  2021-07-02       Impact factor: 14.903

Review 8.  Clinical efficacy of Nafamostat Mesylate in combination with Favipiravir for COVID-19 pneumonia treatment review article.

Authors:  Maram H Abduljabbar
Journal:  Ann Med Surg (Lond)       Date:  2021-07-14

Review 9.  The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management.

Authors:  Mouhamed Yazan Abou-Ismail; Akiva Diamond; Sargam Kapoor; Yasmin Arafah; Lalitha Nayak
Journal:  Thromb Res       Date:  2020-06-20       Impact factor: 3.944

Review 10.  Management of Thrombotic Complications in COVID-19: An Update.

Authors:  Adrija Hajra; Sheetal Vasundara Mathai; Somedeb Ball; Dhrubajyoti Bandyopadhyay; Maedeh Veyseh; Sandipan Chakraborty; Carl J Lavie; Wilbert S Aronow
Journal:  Drugs       Date:  2020-10       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.